Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 348

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 348
---
 by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions.There were no marketable securities as of September 30, 2025 and December 31, 2024, respectively. There were no impairments recorded during the three and nine months ended September 30, 2025 or September 30, 2024. Realized gains and losses are included in other income (expense) on the condensed consolidated statements of operations. During the three and nine months ended September 30, 2025 and 2024, the Company recognized no year-to-date credit loss related to its short-term investments, and had no allowance for credit loss recorded as of September 30, 2025 or December 31, 2024.

Note 4 – Fair Value Measurements

We record cash equivalents and marketable securities at fair value. ASC 820, Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities.Level 2 – Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.Level 3 – Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.The following table summarizes our cash equivalents measured at fair value on a recurring basis as of September 30, 2025:Level 1Level 2Level 3TotalAssets:Cash equivalentsMoney market$227,298,976 $— $— $227,298,976 Total cash equivalents$227,298,976 $— $— $227,298,976 There have been no changes to the valuation methods during the nine months ended September 30, 2025. There were no transfers between Level 1 and Level 2 and we had no financial assets or liabilities that were classified as Level 3 at any point during the nine months ended September 30, 2025. Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently, at the end of each reporting period, valued utilizing third-party